Copyright
©The Author(s) 1997.
World J Gastroenterol. Mar 15, 1997; 3(1): 43-46
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Table 3 Short term therapeutic effects, post treatment survival rate of the treatment group and control (A, B, C) groups
| Therapeutic effect | Treatment group1 | Control groups | ||||
| A | B | C | ||||
| 22 | 162 | 25 | 172 | 21 | 25 | |
| CR + PR | 31.6 (6/19) | 37.5 (6/16) | 4.0 (1/25) | 5.9 (1/17) | 4.8 (1/21) | 8.0 (2/25) |
| CR + PR + MR | 42.1 (8/19) | 43.8 (7/16) | 16.0 (4/25) | 23.5 (4/17) | 28.6 (6/21) | 20.0 (5/25) |
| Survival ≥ 6 mon | 68.4 (13/19) | 75.0 (12/16) | 28.0 (7/25) | 41.2 (7/17) | 42.9 (9/21) | 52.0 (13/25) |
| Survival ≥ 12 mon | 47.1 (8/17) | 57.1 (8/14) | 16.0 (4/25) | 23.5 (4/17) | 9.5 (2/21) | 8.0 (2/25) |
| Still alive | 7 | 7 | 1 | 1 | 0 | 0 |
- Citation: Wu YD, Yang KZ, Zhou DN, Gang YQ, Song XQ, Hu XH, Huang BY. Clinical observation of 125I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma. World J Gastroenterol 1997; 3(1): 43-46
- URL: https://www.wjgnet.com/1007-9327/full/v3/i1/43.htm
- DOI: https://dx.doi.org/10.3748/wjg.v3.i1.43